Profound Medical, Telix sign co-education deal pairing PSMA-PET imaging with TULSA-PRO therapy

Profound Medical Corp.

Co-education agreement pairs Telix's PSMA-PET agents Gozellix and Illuccix with Profound's MRI-guided, incisionless TULSA-PRO platform in prostate care.
Planned initiatives: medical society meetings, KOL programs, educational summits, speaker programs, webinars, clinical case studies and best-practice content.
Profound is developing PSMA-PET-MR image fusion for a planned future Treatment Delivery Console software release; no financial terms were disclosed.
CEO Arun Menawat cites increased access to urologists via Telix; Telix Precision Medicine CEO Kevin Richardson cites more personalized patient care.
CTO Mathieu Burtnyk: ~85% of prostate cancers are multifocal while ~15% are unifocal; ~15-25% of patients are focal-ablation candidates.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.